Radiation dosimetry is the cornerstone of safe radiopharmaceutical development, bridging preclinical biodistribution data with human dose estimation to ensure both therapeutic efficacy and patient safety. At Protheragen, we provide end-to-end radiation safety and dosimetry compliance services that empower sponsors to navigate the complex regulatory landscape-from preclinical imaging and dose extrapolation to IND submission-ready documentation-with precision and confidence.
Radiation dosimetry in the context of radiopharmaceutical development refers to the quantitative assessment of radiation energy absorbed by tissues and organs following administration of a radiolabeled compound. This discipline is fundamental to both diagnostic and therapeutic radiopharmaceuticals: for diagnostics, it ensures that the radiation exposure to patients remains within acceptable safety limits while maintaining image quality; for therapeutics, it establishes the dose-response relationship that underpins efficacy and identifies organ-at-risk toxicity thresholds. The process involves measuring the time-dependent biodistribution of the radiopharmaceutical-typically through serial quantitative imaging such as PET or SPECT-followed by mathematical integration of activity over time to derive time-integrated activity coefficients, which are then combined with dose conversion factors to calculate absorbed doses in Gray (Gy) or equivalent doses in Sievert (Sv). Regulatory agencies including the FDA and EMA mandate robust dosimetric data as part of IND applications, requiring sponsors to demonstrate a reasonable calculation of radiation-absorbed dose to the whole body and critical organs before first-in-human studies can commence.
Fig 1. Decay of 225Ac via neptunium series. (Serencsits, Brian, et al., 2022)
Beyond the computational aspects, radiation safety and dosimetry compliance encompass a comprehensive framework of personnel protection, facility infrastructure, waste management, and regulatory adherence. Preclinical facilities must implement an As Low As Reasonably Achievable (ALARA) program, maintain qualified Radiation Safety Officers (RSOs), and ensure proper shielding, ventilation, and contamination control measures are in place. The biodistribution and dosimetry data generated from animal studies-typically involving tissue sampling, quantitative imaging, and excretion analysis-must be meticulously documented and extrapolated to human equivalents using established scaling methods. This translational step is critical, as it informs the starting dose for Phase 0 or Phase 1 clinical trials and helps anticipate potential radiotoxicities to organs such as the bone marrow, kidneys, liver, and gonads. With the rapid expansion of targeted radionuclide therapies using alpha-emitters like Actinium-225 and beta-emitters like Lutetium-177, the demand for rigorous, GLP-compliant preclinical dosimetry services has never been greater.
Protheragen delivers integrated radiation safety and dosimetry compliance solutions designed to accelerate your radiopharmaceutical program from preclinical concept to clinical readiness. Our multidisciplinary team combines expertise in radiochemistry, molecular imaging, medical physics, and regulatory affairs to provide a seamless, one-stop service platform.
Design and execution of GLP-compliant biodistribution studies using small-animal PET/CT and SPECT/CT imaging. Longitudinal imaging in the same subject to track radiopharmaceutical uptake, retention, and clearance kinetics across tumors and normal organs.
Quantitative analysis of time-activity curves (TACs), calculation of time-integrated activity coefficients, and extrapolation of animal organ doses to human equivalent doses using established scaling methodologies (MIRD, RADAR, ICRP).
Establishment and oversight of ALARA programs, personnel dosimetry monitoring, contamination survey protocols, and radiation safety training. Support for RSO qualification and regulatory inspections.
Development of imaging acquisition protocols optimized for your radionuclide, including scanner calibration, phantom validation, reconstruction parameters, and multi-center harmonization strategies.
Specialized dosimetry for high-LET alpha emitters, including micro-scale dose distribution analysis at the cellular and sub-cellular level to evaluate targeted therapeutic window and potential radiotoxicity.
Protheragen stands at the intersection of radiopharmaceutical innovation and regulatory excellence, offering a differentiated partnership model that combines deep technical expertise with operational agility.
Ready to advance your radiopharmaceutical program with confidence? Contact us today to discuss your preclinical radiation safety and dosimetry needs. Our team is prepared to design a tailored compliance strategy that aligns with your development timeline and regulatory objectives. Whether you are preparing for IND submission or optimizing your therapeutic dosing strategy, Protheragen is your trusted partner from bench to bedside. Reach out to us now and let us help you bring your radiopharmaceutical innovation to patients safely and efficiently.
Reference